Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis at Mayo Clinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years. Usually, seroneg RA means seroneg RA! #ACR24 Elena MyasoedovaMD ☀️ ABST0458 Dr. John Cush

If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627

Less than 1 in 10 referrals for +ANA were associated with #autoimmune diseases ▶️7% had autoimmune diseases ▶️7% had #rheumatology diseases ▶️86% had no rheumatologic diseases #ACR24 #ACR2024 abstract 0318 👉🏽acrabstracts.org/abstract/the-r… #antibodies #antibody

Recommendations for pharmacologic treatment of rheumatoid arthritis-associated interstitial lung disease in the 2023 ACR/CHEST guideline #Rheumatology #RheumatoidArthritis #InterstitialLungDisease #DMARDs #Antifibrotics *From: Saavedra, A.A., Mueller, K.T., Kowalski, E.N. et

🚨 Mind-blowing insights from Georg Schett at #EULAR2025: CAR-T in autoimmune diseases is no longer experimental — it’s revolutionizing care. ✅ Immune reset → drug-free remission ✅ Efficacy in highly-resistant AID ✅ Allogenic & “armed” #CAR_T moving fast into clinics

#neuromodulation in #rheumatoid #arthritis What is it? 👇 Autonomic & immune system interaction Who seeks this Rx? desperate pts w pain No Rx left Interested in technology #EULAR2025 Dr. John Cush EULAR #D2T #RA

Prédiction of PsA from PsO. Stockholm cohort, n=672): •PsA incidence 21.1/1000 PY. •AUC 0.80 for both referral and prognostic models. •Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA. •Early identification feasible. Abstract OP0178 Dr. John Cush

#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis Dr. John Cush

What's the difference between PIPsA & NIPsA? (Persistent Inflammatory confirmed by IMAGING vs. Non inflammatory PsA) 🔹️Cross-sectional study 🔹️517 pts under b/tsDMARDs 🔹️10.3% D2T 🔹️57% PIPsA / 43% NIPsA 👇 Distinct phenotypes 👇 OP0176 #EULAR2025 @rheumnow

Recommendations for #SLE with kidney involvement NEW #EULAR2025 for #LupusNephritis ✅early renal biopsy ✅early combination therapy ✅non-immune treatment

New #EULAR clasificstion for Anti-Synthetase Syndrome [ASyS] #Rheumatology #MedTwitter #Myositis

EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes Amir Mokhtarizadeh 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025

New systematic review by Siniša Savić et al. characterises the complete phenotypic spectrum of VEXAS syndrome. ➡️These findings will facilitate earlier diagnosis, inform monitoring strategies, and guide future research priorities. ➡️bit.ly/40gp76A

Comparison of the Definitions of the Complex to Manage -by GRAPPA- and Difficult to Manage -by EULAR- #Psoriatic_Arthritis As presented at #EULAR2025 by Dr Fabian Proft OP0175 & Dr Helena Marzo-Ortega at the recommendations session Two Frameworks for One Challenge Dr. John Cush

🧯How to treat Macrophage Activation Syndrome in 2025 🔴Take-home points from Dr Nigrovic's talk on Still's Disease 1- Methylprednisolone + Anakinra 2- + Ruxolitinib +/- Tacrolimnus / IVIG / Rituximab 3- Emapalumab 4- Etoposide + Dexamethasone #ACR25 #GlobalSummit

#ReviewCourse #ACR25 vasculitides & CNS involvement 🔹 Takayasu,PAN & ANCA-associated: CNS dysfunction rare but life-threatening. 🔹 GCA/PMR:overlapping inflammatory spectrum. 🔹 Behçet’s: parenchymal vs. cerebral venous thrombosis forms. 💊 Therapy: cyclophosphamide or TNF/IL-6

🧩 #ACR25 Highlight | Skin in the Game: Cutaneous Clues in Rheumatic Disease By Dr. Katharina S. Shaw, Penn Medicine 🧵 Post 1 | Eosinophilic Fasciitis vs Systemic Sclerosis • 💡 Check distal digits → tightening absent in EF, universal in SSc • ✴️ Groove sign &

#ReviewCourse #ACR25 MAS treatment: 🔹Corticosteroids remain first-line 🔹 Anakinra (anti-IL1) improve survival in severe MAS 🔹 Emapalumab (anti-IFNγ) 93% remission in refractory cases; FDA-approved for steroid-refractory Still’s-MAS

The benefits of exercise has been proven for most rheumatic diseases, and there are lots of good reasons why #ACR25 Brian Andonian Dr. John Cush